Table 31GRADE profiles

No. of studiesDesignAmi
(T1)
Gaba
(T2)
Mean change (SD) from baseline
[p-value]
LimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
OTHER NON-PRIMARY OUTCOME: Pain relief (Scale: 5-point Pain Score)
1
(PDN1)
RCT1213Ami = −1.3 (0.6)
Gaba = −1.9 (0.8)
p = 0.026
SaNSbScNVery Low

T1 = treatment 1; T2 = treatment 2; N = No serious; S = Serious; VS = Very serious.

Ami = amitriptyline; Gaba = gabapentin; PDN = painful diabetic neuropathy.

a

Open-label study with no blinding; subjective outcome on pain and global improvement; downgrade 1 level.

b

Indirect outcome measure.

c

Total number of events < 300 owing to small study sample.

1

Dallocchio et al. (2000)

Open-label study with no blinding; subjective outcome on pain and global improvement; downgrade 1 level.

Indirect outcome measure.

Total number of events < 300 owing to small study sample.

From: 2, How this guideline was developed

Cover of Neuropathic Pain
Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings.
NICE Clinical Guidelines, No. 96.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.